This page lists 15 named compounds from companies that describe their discovery platforms as AI-driven, with the phase and status shown on ClinicalTrials.gov on November 13, 2026. Two are in Phase 3: rentosertib from Insilico Medicine and GB-0895 from Generate Biomedicines. No regulator has approved a drug from this list. A trial phase says how far testing has gone. It does not say that a drug works.
Phase 3
| Compound | Company | Condition | Registry ID | Status | Start date | Planned enrolment |
|---|---|---|---|---|---|---|
| Rentosertib (INS018_055) | Insilico Medicine | Idiopathic pulmonary fibrosis | NCT07687459 | Recruiting | September 9, 2026 | 320 |
| GB-0895, SOLAIRIA-1 | Generate Biomedicines | Severe asthma | NCT07276724 | Recruiting | December 3, 2025 | 786 |
| GB-0895, SOLAIRIA-2 | Generate Biomedicines | Severe asthma | NCT07359846 | Recruiting | January 20, 2026 | 786 |
Rentosertib. Insilico announced "the initiation" of the Phase 3 trial on July 7, 2026. The registry shows an actual start date of September 9, 2026. We found no source explaining the gap, and the release did not say a patient had been dosed. The trial is randomised, double-blind and placebo-controlled, at 47 centres in China, with once-daily dosing for 52 weeks. Insilico says the target was identified with its AI software and the molecule designed with generative AI. The registry lists primary completion as estimated for October 30, 2029.
GB-0895. An antibody against TSLP. Generate says it is the first biologic engineered with an AI-enabled platform to reach Phase 3. That is the company's own claim.
Phase 1 and Phase 2
| Compound | Company | Condition | Phase | Registry ID | Status |
|---|---|---|---|---|---|
| ISM5411 | Insilico Medicine | Ulcerative colitis | 2 | NCT07265570 | Recruiting |
| Rentosertib, second Phase 2 study | Insilico Medicine | Idiopathic pulmonary fibrosis | 2 | NCT05975983 | Recruiting |
| ISM3412 | Insilico Medicine | Advanced solid tumours | 1/2 | NCT06414460 | Recruiting |
| ISM6331 | Insilico Medicine | Mesothelioma and other solid tumours | 1/2 | NCT06566079 | Recruiting |
| ISM8207 | Insilico Medicine | Solid tumours and B-cell lymphoma | 1 | NCT06445517 | Recruiting |
| ISM8969 | Insilico Medicine | Healthy and obese adult volunteers | 1 | NCT07581431 | Recruiting, started June 15, 2026 |
| ISM9528 | Insilico Medicine | Healthy volunteers | 1 | NCT07932041 | Recruiting, started October 29, 2026 |
| ISM5939 | Insilico Medicine | Advanced solid tumours | 1 | NCT06724042 | Not yet recruiting |
| XL309 (ISM3091) | Exelixis, licensed from Insilico | Advanced solid tumours | 1 | NCT05932862 | Active, not recruiting |
| REC-4881 | Recursion | Familial adenomatous polyposis | 1/2 | NCT05552755 | Recruiting |
| REC-617 (GTAEXS617) | Recursion, through its Exscientia unit | Advanced solid tumours | 1/2 | NCT05985655 | Recruiting |
| REC-1245 | Recursion | Advanced cancers and lymphomas | 1/2 | NCT06678659 | Recruiting |
| REC-994 | Recursion | Cerebral cavernous malformation | 2 | NCT05085561 | Completed |
| IAM1363 | Iambic Therapeutics | HER2 cancers | 1/1b | NCT06253871 | Recruiting |
A second Recursion study of REC-4881, in cancers with AXIN1 or APC mutations (NCT06005974), is listed as terminated.
Not on the List, and Why
- Isomorphic Labs. No trial is registered under its name. See Isomorphic Labs funding and clinical trial status.
- Anthropic. Its own programmes are preclinical. The company says a first trial could start as soon as late 2028. See Anthropic life sciences partnerships.
- Zasocitinib (TAK-279), Takeda. The FDA accepted its application for plaque psoriasis under priority review, Takeda said on September 14, 2026, with a decision date in the first quarter of 2027. It is sometimes described as computationally designed. Whether that counts as AI-designed is disputed, so we have left it out of the tables.
How Many Are There in Total?
Counts differ because there is no agreed definition of "AI-designed". Two figures circulate in 2026 coverage and we could trace neither to a primary source.
- An analysis presented at the ASCO meeting in 2026 counted 117 AI-enabled assets from 63 companies that had entered human trials, of which 60 had completed Phase 1 and 8 had completed Phase 2, according to a summary by IntuitionLabs.
- Several articles cite more than 173 programmes in clinical development. We could not find where that number comes from.
Insilico alone reports 13 clearances to begin human testing and 8 ongoing Phase 1 trials in its July 2026 release.
Methodology
Phase, status, start date and enrolment were read from the ClinicalTrials.gov API on November 13, 2026, by searching each compound name and the sponsor. Inclusion follows each sponsor's own description of its platform as AI-driven. We did not verify how much of each molecule's design was done by AI. The rentosertib details are from Insilico's July 7 release, the GB-0895 claim from Generate's second-quarter update, the zasocitinib status from Takeda, and the ASCO count from IntuitionLabs. The list is not complete. This page is not medical advice.